Syngene International delivered a weak set of fourth-quarter numbers for FY26 on Wednesday — profit fell 19%, EBITDA dropped 12% and margins contracted by 450 basis points — and yet the stock surged nearly 8% to Rs 466, touching an intraday high of Rs 484.90. The divergence between the results and the market reaction is the real story here.
| Metric | Q4 FY26 | Q4 FY25 | YoY Change |
|---|---|---|---|
| Revenue | Rs 1,036.5 Cr | Rs 1,018 Cr | +1.8% |
| EBITDA | Rs 303.4 Cr | Rs 343.6 Cr | -11.7% |
| EBITDA Margin | 29.3% | 33.8% | -450 bps |
| Net Profit | Rs 147.9 Cr | Rs 183.3 Cr | -19.3% |
Revenue barely moved — up just 1.8% year-on-year to Rs 1,036.5 crore from Rs 1,018 crore — pointing to a period of muted volume growth. EBITDA fell 11.7% to Rs 303.4 crore as the margin compressed to 29.3% from 33.8% — a 450 basis point deterioration that reflects both the flat revenue base and cost pressures likely linked to continued investment in infrastructure, Mangalore biologics facility scale-up costs, and talent. Net profit declined 19.3% to Rs 147.9 crore from Rs 183.3 crore, with higher depreciation from ongoing capex deepening the bottom-line pressure beyond what the EBITDA decline alone would imply.
Why the stock is rallying despite the weak numbers
The answer lies in where Syngene was before the results and what the market was pricing in. The stock had already fallen sharply from its 52-week high of Rs 728.60 to a low of Rs 380 — a near 48% decline — meaning a significant amount of bad news had been discounted long before today’s results. At Rs 466, the stock is still down 36% from its peak, suggesting the market is not rewarding a beat but rather relieved the results were not worse than feared.
Additionally, Syngene is a long-duration, capital-heavy contract research and manufacturing organisation that investors typically evaluate on a multi-year basis rather than a single quarter. The Mangalore biologics facility — one of the largest biologics CDMO investments in India — has been in ramp-up mode and is expected to be a meaningful revenue contributor as it reaches optimal utilisation. Margin compression during such investment phases is anticipated, not alarming, in the context of the growth trajectory being built.
The stock also trades at a PE of 53.50 and a market cap of approximately Rs 18,752 crore — a premium multiple that reflects the structural opportunity in India’s CDMO space rather than near-term earnings momentum.
The 8% rally, in this context, looks less like enthusiasm about the numbers and more like relief that the worst-case scenarios some investors had been pricing in did not materialise.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Please consult a qualified financial advisor before making investment decisions.